Botox for sweating how many units

You can talk to your doctor or insurance company about getting your Botox injections covered. Hyperhidrosis can be uncomfortable.

Learn what causes it, and explore treatment options that can provide relief. Also called perspiration, sweating is the release of a…. Although perspiring is completely healthy and natural, there may be times when you want to know how to stop sweating. Here's what you can do. The masseter muscle is located in the cheek area. Getting Botox in this muscle may relieve teeth grinding or jaw clenching. It can also contour your…. There are three FDA-approved uses for Botox on the forehead.

However, being injected with too much of the toxin has negative and harmful side effects…. A Botox party is a social event where people get together, often at someone's home, to get Botox injections.

However, there are certain risks to keep…. Many people desire hollow cheeks, the appearance of having little fat in the area between the cheekbones and jawbone, because they find they look…. Health Conditions Discover Plan Connect. How do Botox injections work? Where is Botox used?

How do I prepare for the procedure? How much does it cost? What are the risks and side effects? What to expect after treatment. Bottom line. Read this next. Medically reviewed by Elaine K. Luo, M. As always, seek proper consultation before treatment and best of luck! Hi BR. As another physician has mentioned, Botox Dysport injections do depend on the skill of the injector so if you were injected by someone that was not trained well on underarm injections, then it's possible the product could have wound up at the wrong depth.

If it was working with your previous injector, best bet is to return to that person. Best of luck. Using Botox for sweaty palms works very well. Hello and Thank you for asking this question. Some of my Dermatology clinics see significant traffic of patients seeking this treatment for excessive sweating, however we are finding that few cases are being approved by insurance for coverage of treatment using Botox. There are a series of other Hyperhidrosis is a condition where a concentration of excess sweating occurs most commonly in the hands, feet, axillae underarm , and groin.

The most minimally invasive treatment to improve this is to injecting Botox directly into the overactive muscles and sweat glands.

We typically start by I got units of Botox underarm sweating and sweating worse than before. What could have gone wrong? There was no serious adverse event during 96 weeks of follow-up. No patient withdrew from the study for treatment-related reasons. Minor adverse effects included stinging during injection, skin irritation, and mild fatigue after injection. All symptoms resolved without additional treatment in 1 to 4 days. We conducted a randomized, multicenter clinical trial of a side-by-side comparison with U and U of botulinum toxin A injections in patients with axillary hyperhidrosis.

Over a week follow-up period in which patients were re-treated using the same side-specific doses, we found no difference in the results between the 2 doses at any given point. The results were established using gravimetric measurement of sweat production, which has become a standard objective parameter in clinical trials of hyperhidrosis. Subjectively, the patients felt that their sweating after 36 weeks or more had come closer to baseline sweating compared with what could be measured objectively.

An explanation for this finding may be that during the first months after treatment, patients hardly sweat at all. This effect should be taken into consideration when treatment intervals are being determined. The study could be criticized because it was not placebo controlled or double-blind. However, the efficacy of botulinum toxin A over placebo has already been well established in previous placebo-controlled, double-blind studies.

When we compared the results of the first and the second treatment cycles, we found both treatments to be equally effective in reducing sweating initially. However, 48 weeks after the second treatment, the sweat rates were significantly lower than those 48 weeks after the first treatment. This outcome may be attributed to the reassuring experience of patients that their symptoms can be controlled by repetitive treatments, a process that counteracts a vicious cycle of self-consciousness and sweating.

This hypothesis is supported by recent findings that botulinum toxin A treatments can restore quality of life and resolve social phobia. It has to be emphasized, however, that comparison of clinical outcomes after the use of Botox vs Dysport should be made with caution because of the disparity of the respective units 12 - 14 as well as additional factors, including tissue-specific spreading or protein load. Instead of comparing different products, it is more accurate to compare 2 doses of the same product to optimize treatment regimens.

Based on the results of our study, we conclude that and U doses of Dysport are equally effective in short- and long-term results. In view of cost-effectiveness and avoidance of adverse effects, including induction of antibodies, U of Dysport should be the preferred dose for treating axillary hyperhidrosis. Author Contributions: Study concept and design : Heckmann and Plewig.

Acquisition of data : Heckmann and Hyperhidrosis Study Group. Analysis and interpretation of data : Heckmann and Plewig. Drafting of the manuscript : Heckmann. Critical revision of the manuscript for important intellectual content : Heckmann and Plewig.

Administrative, technical, and material support : All authors. Dr Heckmann has received research grants from Allergan, Irvine, Calif, and Ipsen Ltd, Wrexham, England, both manufacturers of botulinum toxin for other research projects. Role of the Sponsor: The sponsor, Ipsen-Pharma, supplied botulinum toxin A Dysport but did not design the study; collect, analyze, or interpret data; or write any part of the article.

Acknowledgment: Multicenter data management I. Mohr, MD, and C. Hautmann, MD and statistical analysis D. Albrecht, A. Oppers, A. Peschen, W. Prager, S. Sacher, C. Lietzberg, P. Feller, B. Breit, M. Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy Continue. Figure 1. View Large Download.